27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Raymond James has downgraded Gossamer Bio Inc (NASDAQ:GOSS) to Market Perform from Outperform following the publication of sotatercept's Phase 3 data in NEJM.
- The analyst has already thought that seralutinib would exhibit weaker efficacy than Merck & Co Inc's (NYSE:MRK) sotatercept in comparable populations.
- Using Hodges-Lehman location shift (HLLS) statistic for 6MWD, Merck reported a difference of 40.8m in Phase 3 compared to LSMD of 24.9m in Phase 2, which makes the development path for seralutinib even more difficult.
- Sotatercept reduced the risk of clinical worsening or death by 84%, supporting the adoption as the new standard of care on top of existing therapies.
- Raymond James writes that Gossamer may need to run another Phase 2 as an add-on to sotatercept or a Phase 3 in FC III patients only.
- Although Gossamer has additional development plans for seralutinib in pulmonary hypertension (PH) due to interstitial lung disease (PH-ILD), a confirmed plan is required.
- The analyst also writes that while PAH program discontinuation would still be a negative catalyst, the market may view the event positively. Gossamer's CNS penetrant BTKi GB5121 currently offers an upside.
- Price Action: GOSS shares traded flat at $1.74 on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!